VHT stock sentiment todayVanguard Health Care Index Fund ETF Shares

A defensive powerhouse poised to benefit from an aging demographic and a recovery in biotech, offered at an industry-leading expense ratio.

Full model breakdown (analyst / gossip / momentum weights) is a Pro feature. Modelled for VHT. Not financial advice.

Market narrative is shifting toward defensive sectors as investors hedge against economic cooling; healthcare is seen as a 'safe haven' with secular growth tailwinds from AI drug discovery and GLP-1 weight-loss drug expansion.

• ·GLP-1 mania (Eli Lilly/Novo Nordisk dominance)
• ·M&A activity resurgence in biotech
• ·Defensive rotation amid election year volatility
• ·Medicare price negotiation fears subsiding

VHT offers diversified exposure to 400+ healthcare stocks with a rock-bottom 0.10% expense ratio. It maintains a superior ROE and stronger balance sheet profile compared to broader market indices due to high-margin pharma and medical device constituents.

• ·Expense Ratio: 0.10% (89% lower than peer average)
• ·P/E Ratio: ~20.5x (Attractive vs. S&P 500 growth)
• ·Dividend Yield: ~1.3%
• ·Top Holdings: UnitedHealth, Eli Lilly, Johnson & Johnson

• ·Regulatory pressure on drug pricing (Inflation Reduction Act)
• ·Concentration risk in top 10 holdings (approx. 48% of fund)
• ·High sensitivity to clinical trial failures in the biotech sub-sector

How direct competitors stack up against VHT right now.

• NEUTRAL
  XLVHealth Care Select Sector SPDR Fund

  COLDER — Less diversified with only ~70 holdings, missing the high-growth small-cap biotech exposure that VHT captures.

  See full analysis →
• HOT
  IBBiShares Biotechnology ETF

  HOTTER — Higher risk/reward profile with aggressive exposure to gene editing and AI-driven R&D catalysts that VHT dilutes.

  See full analysis →
• NEUTRAL
  IXJiShares Global Healthcare ETF

  COLDER — Trading at a similar multiple but carries higher currency risk and lacks the concentrated US-market innovation lead.

  See full analysis →